|
Immunotherapy
Citations 1-10 of 576 total displayed.
|
Most recent content
(15 Jul 2008):
|
Tumor-specific Th17-polarized cells eradicate large established melanoma
- Pawel Muranski, Andrea Boni, Paul A. Antony, Lydie Cassard, Kari R. Irvine, Andrew Kaiser, Chrystal M. Paulos, Douglas C. Palmer, Christopher E. Touloukian, Krzysztof Ptak, Luca Gattinoni, Claudia Wrzesinski, Christian S. Hinrichs, Keith W. Kerstann, Lionel Feigenbaum, Chi-Chao Chan, and Nicholas P. Restifo
Blood 2008; 112: 362-373.
[Abstract]
[Full text]
[PDF]
|
Past content
(since Jun 2000):
|
Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia
- Nicholas B. Heaney, Mhairi Copland, Karen Stewart, Judith Godden, Anne N. Parker, I. Grant McQuaker, Graeme M. Smith, Charles Crawley, Pat Shepherd, and Tessa L. Holyoake
Blood 2008; 111: 5252-5255.
[Abstract]
[Full text]
[PDF]
DDX3Y encodes a class I MHC–restricted H-Y antigen that is expressed in leukemic stem cells
- Kellie V. Rosinski, Nobuharu Fujii, Jeffrey K. Mito, Kevin K. W. Koo, Suzanne M. Xuereb, Olga Sala-Torra, James S. Gibbs, Jerald P. Radich, Yoshiki Akatsuka, Benoît J. Van den Eynde, Stanley R. Riddell, and Edus H. Warren
Blood 2008; 111: 4817-4826.
[Abstract]
[Full text]
[PDF]
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique
- Stephan Mielke, Raquel Nunes, Katayoun Rezvani, Vicki S. Fellowes, Annie Venne, Scott R. Solomon, Yong Fan, Emma Gostick, David A. Price, Christian Scotto, Elizabeth J. Read, and A. John Barrett
Blood 2008; 111: 4392-4402.
[Abstract]
[Full text]
[PDF]
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells
- Christian Schütz, Martin Fleck, Andreas Mackensen, Alessia Zoso, Dagmar Halbritter, Jonathan P. Schneck, and Mathias Oelke
Blood 2008; 111: 3546-3552.
[Abstract]
[Full text]
[PDF]
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
- Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter T. Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah Thomas, Robert D. Knight, Michele Schmidt, Kenton Wride, Jerome B. Zeldis, and Alan F. List
Blood 2008; 111: 86-93.
[Abstract]
[Full text]
[PDF]
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
- Katayoun Rezvani, Agnes S. M. Yong, Stephan Mielke, Bipin N. Savani, Laura Musse, Jeanine Superata, Behnam Jafarpour, Carol Boss, and A. John Barrett
Blood 2008; 111: 236-242.
[Abstract]
[Full text]
[PDF]
PKC  –mTOR pathway: a new target for rituximab therapy in follicular lymphoma
- Ludivine Leseux, Guy Laurent, Camille Laurent, Maxime Rigo, Amandine Blanc, Daniel Olive, and Christine Bezombes
Blood 2008; 111: 285-291.
[Abstract]
[Full text]
[PDF]
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
- Xing Du, Satoshi Nagata, Tomoko Ise, Maryalice Stetler-Stevenson, and Ira Pastan
Blood 2008; 111: 338-343.
[Abstract]
[Full text]
[PDF]
Impaired T-cell priming in vivo resulting from dysfunction of WASp-deficient dendritic cells
- Gerben Bouma, Siobhan Burns, and Adrian J. Thrasher
Blood 2007; 110: 4278-4284.
[Abstract]
[Full text]
[PDF]
|
|
